Liquidia stock price rebounds today after Tuesday tumble as options heat up
Liquidia stock rebounded by roughly 2% on Wednesday after an 11% drop the previous day, which saw a significant increase in bearish put options. Investors are closely watching for the company's full-year audited financial results and developments in its patent dispute with United Therapeutics, as the future of its key product, YUTREPIA, hinges on these factors. The rebound signals a sensitive period for Liquidia, with daily price swings expected to be volatile leading up to February options expiry.
CenterBook Partners LP Decreases Stock Holdings in Liquidia Corporation $LQDA
CenterBook Partners LP significantly decreased its stake in Liquidia Corporation (NASDAQ:LQDA) by 56.1% in the third quarter of 2025, selling over 619,000 shares. Despite this, other institutions like Vanguard and Caprock Group increased their holdings, with institutional investors owning 64.54% of the company. Analyst ratings are generally favorable, with a "Moderate Buy" consensus and a target price of $39.67.
Liquidia Target of Unusually Large Options Trading (NASDAQ:LQDA)
Liquidia (NASDAQ:LQDA) recently experienced unusually large options trading, with a significant increase in put option purchases as its stock price fell. This comes amidst notable insider selling from General Counsel Russell Schundler and insider Rajeev Saggar, though institutional ownership remains strong at 64.54% and analysts maintain a "Moderate Buy" rating. The company's stock performance shows it trading below its 50-day simple moving average but above its 200-day simple moving average, while some analysts have recently adjusted price targets, with HC Wainwright raising its target to $50.
Liquidia Corporation (LQDA) Gains Momentum Following Overturning of District Court Patent Ruling
Arquitos Capital Partners reported a significant 82.1% net return in 2025, largely driven by its investment in Liquidia Corporation (LQDA). Liquidia's stock surged after a district court's patent ruling, initially unfavorable to Liquidia, was overturned because the patent in question, owned by competitor United Therapeutics, was found invalid by the Patent Trial and Appeals Board. This development made Liquidia the largest contributor to Arquitos Capital's portfolio in 2025.
Liquidia Corporation (LQDA) Gains Momentum Following Overturning of District Court Patent Ruling
Liquidia Corporation (LQDA) is gaining momentum following the overturning of a District Court patent ruling, as highlighted in Arquitos Capital Partners' Q4 2025 investor letter. Arquitos Capital Management saw an 82.1% net return in 2025, with Liquidia being its largest contributor due to its strong performance, driven by company-specific factors in a selective market. While Arquitos Capital Partners acknowledges the potential of Liquidia, they suggest that certain AI stocks might offer higher returns in a shorter timeframe.
Liquidia Corporation (NASDAQ:LQDA) Given Average Recommendation of "Moderate Buy" by Brokerages
Liquidia Corporation (NASDAQ:LQDA) has received an average "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $39.67. This comes amidst significant insider selling, where executives sold over 250,000 shares worth $9.17 million in the last three months, though insiders still collectively own 26.5% of the shares. The company's stock opened at $38.20 and has a market capitalization of $3.32 billion, reflecting its clinical-stage status.
LQDA April 2nd Options Begin Trading
New options for Liquidia Corp (LQDA) with an April 2nd expiration began trading, presenting potential opportunities for investors. A put contract at a $39.00 strike price offers a lower cost basis if assigned, while a covered call strategy at a $41.00 strike could yield a 16.26% return if the stock is called away. Both strategies involve analyzing implied and historical volatility to assess potential outcomes.
While Liquidia (NASDAQ:LQDA) shareholders have made 991% in 5 years, increasing losses might now be front of mind as stock sheds 9.3% this week
Liquidia Corporation (NASDAQ:LQDA) shareholders have seen a 991% return over the past five years, with a 39% increase in the last quarter. Despite this strong long-term performance, the company's recent 9.3% stock drop highlights concerns over increasing losses. Analysts note the company's robust 36% annual revenue growth over the last five years, indicating potential for continued future growth despite current unprofitability.
EXEL or LQDA: Which Is the Better Value Stock Right Now?
This article evaluates Exelixis (EXEL) and Liquidia Corporation (LQDA) as potential value stock investments in the Medical - Biomedical and Genetics sector. Based on Zacks Rank and various valuation metrics like P/E, PEG, and P/B ratios, EXEL is identified as the better value option with a Zacks Rank of #1 (Strong Buy) and a Value grade of B, compared to LQDA's Zacks Rank of #2 (Buy) and a Value grade of D.
Caprock Group LLC Purchases New Shares in Liquidia Corporation $LQDA
Caprock Group LLC has acquired a new position in Liquidia Corporation (NASDAQ:LQDA), purchasing over 1.6 million shares valued at approximately $37.1 million, making Liquidia its 20th largest holding. Other institutional investors like MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. and Goldman Sachs Group Inc. also increased their stakes in Liquidia. This news comes alongside reports of insider stock sales by CFO Michael Kaseta and insider Rajeev Saggar, as well as updated analyst ratings for the company.
Liquidia Technologies stock hits 52-week high at 43.0 USD
Liquidia Technologies (LQDA) stock reached a 52-week high of $43.00, marking a significant milestone for the biotechnology company. The stock has seen a 173.27% increase over the past year and a 110.46% gain in the last six months, driven by strong fundamentals including an 89.11% gross profit margin and 343.41% revenue growth. This performance is further supported by robust preliminary Q4 2025 results for its inhalation treatment, Yutrepia, which exceeded sales expectations and led to raised price targets from analysts.
Surging Revenue And Technical Momentum Could Be A Game Changer For Liquidia (LQDA)
Liquidia Corp (LQDA) has been identified as meeting the Minervini Trend Template, showing strong technical momentum, significant year-over-year revenue growth, and upgraded analyst forecasts. This positions the company as a market leader, attracting investor attention despite inherent risks like continued losses and high valuation. The article suggests that while there may be some downside and divergent fair value estimates, the focus for Liquidia's investment narrative remains on commercialization progress and legal outcomes.
Surging Revenue And Technical Momentum Could Be A Game Changer For Liquidia (LQDA)
Liquidia Corp (LQDA) has been identified as meeting the Minervini Trend Template due to strong technical momentum, significant year-over-year revenue growth, and upgraded analyst revenue forecasts. This combination positions Liquidia as a market leader, attracting investor attention despite existing risks like continued losses, high valuation, and insider selling. The primary investment narrative revolves around YUTREPIA's commercial success following FDA approval and its ability to deliver sustainable profitability amidst ongoing litigation.
Surging Revenue And Technical Momentum Could Be A Game Changer For Liquidia (LQDA)
Liquidia Corp (LQDA) is showing strong technical momentum and significant year-over-year revenue growth, backed by upgraded analyst forecasts and the recent FDA approval of YUTREPIA. While its financial health is strong and it's considered a market leader in its niche, risks like continued losses, high valuation, and insider selling, combined with ongoing litigation and market volatility, suggest potential downside despite its positive trajectory. Investors are urged to conduct further research, given the wide divergence in fair value estimates.
LQDA SEC Filings - Liquidia Corporation 10-K, 10-Q, 8-K Forms
This page provides access to Liquidia Corporation's (LQDA) SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K reports, along with insider trading information. It details crucial company updates such as securing additional financing for YUTREPIA™ commercialization, director stock compensation awards, and results from their annual stockholder meeting. The platform also offers AI-powered summaries to help investors understand complex regulatory disclosures.
Y Intercept Hong Kong Ltd Trims Position in Liquidia Corporation $LQDA
Y Intercept Hong Kong Ltd significantly reduced its stake in Liquidia Corporation (NASDAQ:LQDA) by 58.9% in Q3, selling 36,652 shares, though its remaining 25,583 shares are still valued at approximately $582,000. Despite this institutional selling, analyst sentiment for Liquidia is largely bullish, with a consensus "Moderate Buy" rating and several firms raising price targets, leading to a recent 5.5% increase in share price. Insiders, however, have been net sellers, offloading over 252,000 shares worth about $9.17 million in the past 90 days, even as they retain a substantial 30.1% ownership.
Liquidia Corp (NASDAQ:LQDA) Identified as High-Growth Momentum Candidate by Minervini Trend Template
Liquidia Corp (NASDAQ:LQDA) has been identified as a strong candidate by the Minervini Trend Template and High Growth Momentum (HGM) score, indicating a stock in a confirmed uptrend with improving business results. The company meets key technical requirements, including trading above significant moving averages and exhibiting strong relative strength. Fundamentally, LQDA shows rapid revenue growth, positive analyst sentiment, and a history of beating revenue estimates, although current price volatility suggests waiting for consolidation before entry.
Liquidia reports $148.3M in 2025 YUTREPIA sales
Liquidia announced its 2025 sales figures for YUTREPIA, reporting a total of $148.3 million. This financial update provides key insights into the commercial performance of the drug.
320,597 Shares in Liquidia Corporation $LQDA Purchased by Federated Hermes Inc.
Federated Hermes Inc. has purchased 320,597 shares of Liquidia Corporation (NASDAQ:LQDA), valued at approximately $7.29 million, representing about 0.37% of the company. Institutional investors collectively own 64.54% of Liquidia stock. While analysts maintain a "Moderate Buy" rating with an average target price of $39.67, company insiders have recently sold over $11 million worth of shares, though they still hold 30.10% of the company.
LQDA March 13th Options Begin Trading
New options for Liquidia Corp (LQDA) with a March 13th expiration began trading, with a particular put contract at a $42.00 strike offering a 13.81% return if it expires worthless, and a call contract at a $43.00 strike for a covered call strategy potentially yielding 15.80%. The article details how investors can utilize these options for potential returns or to acquire shares at a discount.
Jason Adair Sells 688 Shares of Liquidia (NASDAQ:LQDA) Stock
Jason Adair, an insider at Liquidia (NASDAQ:LQDA), sold 688 shares of the company's stock on January 26th for a total of $28,655.20, reducing his stake by 0.32% to 211,169 shares. This sale follows previous insider disposals in January, December, and November. Despite the insider selling, Liquidia recently reported strong revenue of $54.34 million against estimates of $18.86 million, and analysts maintain a "Moderate Buy" rating with an average price target of $39.67.
Liquidia (NASDAQ:LQDA) CAO Dana Boyle Sells 1,580 Shares
Liquidia's CAO, Dana Boyle, sold 1,580 shares of the company's stock on January 26th for $65,807, reducing her total stake by 0.88%. This follows other sales in January and December, totaling approximately 12,930 shares worth $489,050. The company recently reported strong quarterly revenue growth and trades near its 52-week high, with a "Moderate Buy" consensus analyst rating.
Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress
Liquidia Corporation announced it will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress, showcasing clinical data for LIQ861 (YUTREPIA) and L606. The presentations will cover interim data from the ASCENT study evaluating LIQ861 in PH-ILD, as well as 48-week open-label data for L606 in PAH and PH-ILD. These presentations highlight the potential impact of Liquidia's therapies for patients with challenging respiratory and vascular diseases.
Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress
Liquidia Corporation announced it will present three posters at the Pulmonary Vascular Research Institute 2026 Annual Congress. These presentations will highlight clinical data for LIQ861 (YUTREPIA™) and L606 in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is excited to showcase its data and its potential impact on patients and the global medical community.
Liquidia brings inhaled PAH, PH-ILD data to PVRI 2026 in Dublin
Liquidia (NASDAQ: LQDA) announced it will present three clinical posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress in Dublin, Ireland, from January 28 to February 1, 2026. The presentations will include interim and open-label data for its inhaled treprostinil products, LIQ861 (YUTREPIA) in PH-ILD from the ASCENT study and investigational L606 in PAH and PH-ILD. This showcases the company's progress in developing therapies for challenging respiratory and vascular diseases.
Liquidia to Present Clinical Data Across Its Portfolio at
Liquidia Corporation announced it will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress in Dublin, Ireland. These presentations will highlight clinical data for LIQ861 (YUTREPIA) and L606, an investigational extended-release treprostinil, across pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company expressed excitement about showcasing the strength and breadth of their data and its potential impact on patients.
Liquidia Corporation (LQDA) Investor Outlook: A Biotech Stock Riding High on 1,121.70% Revenue Growth
Liquidia Corporation (LQDA) is a biotech company specializing in treatments for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), showing remarkable 1,121.70% revenue growth amidst heavy investment in R&D. Despite a negative EPS and free cash flow, analysts are predominantly positive, with an average target price suggesting a modest upside, and technical indicators showing strong bullish momentum but also an overbought condition. The company's product pipeline, including YUTREPIA and L606, and strategic partnerships, position it as a compelling, high-risk opportunity in the biotech sector.
Liquidia to Present Clinical Data Across Its Portfolio at
Liquidia Corporation announced it will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress. The presentations will highlight clinical data for LIQ861 (YUTREPIA™) and L606 in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). These presentations aim to showcase the strength of their data and its potential impact on patient care and the medical community.
Liquidia Technologies stock hits all-time high at 41.77 USD
Liquidia Technologies' stock hit an all-time high of $42.15 USD, outperforming its previous 52-week high after a significant 186.63% surge in the past year. The company, which boasts a market capitalization of $3.55 billion and high gross profit margins, also reported strong preliminary Q4 2025 revenue of $90.1 million for its inhalation treatment, Yutrepia, exceeding analyst expectations and leading to increased price targets from Jefferies and BTIG.
Liquidia Corporation (NASDAQ:LQDA) Given Average Rating of "Moderate Buy" by Analysts
Eleven analysts have assigned Liquidia Corporation (NASDAQ:LQDA) an average "Moderate Buy" rating with a 12-month target price of $39.67. Despite significant insider selling totaling over $11 million in the last 90 days, the company reported strong Q3 revenue of $54.34 million, beating estimates, though it remains unprofitable with negative margins. Liquidia, a biopharmaceutical company, focuses on improving drug delivery through its PRINT® platform, with its lead product LIQ861 targeting pulmonary arterial hypertension.
Liquidia Corp and MP Materials See Surge in Options Trading Volume
Liquidia Corp (LQDA) and MP Materials Corp (MP) recently experienced significant surges in options trading volume, indicating heightened investor interest. For Liquidia, a call option expiring January 23, 2026, suggests bullish sentiment, while for MP Materials, a put option for the same expiry points to market concerns over potential downside risks. Analyst ratings for Liquidia are predominantly positive, with several firms raising price targets due to strong Q3 earnings from its Yutrepia product.
How Yutrepia’s Early Traction and Milestones At Liquidia (LQDA) Has Changed Its Investment Story
Liquidia Corporation's lead drug Yutrepia is gaining early commercial traction and hitting clinical milestones, influencing the company's investment narrative. The article explores how Yutrepia's performance, along with its FDA approval and delivery advantages, could drive Liquidia's growth despite challenges like high valuation multiples and ongoing losses. Investors are considering whether Yutrepia can justify the company's current valuation, with key catalysts including continued prescription uptake and progress toward a $100 million net sales milestone.
Liquidia Corporation (NASDAQ:LQDA) Short Interest Update
Liquidia Corporation (NASDAQ:LQDA) experienced an 18.1% decrease in short interest in December, bringing it to 10.7 million shares, representing 17.6% of the float. Despite a significant revenue beat in its last earnings report and some positive analyst ratings, the company remains unprofitable. Insider selling activity was notable, with the CEO and General Counsel selling shares totaling over $3.5 million in January, although insiders still own a substantial portion of the company.
How Yutrepia’s Early Traction and Milestones At Liquidia (LQDA) Has Changed Its Investment Story
Liquidia Corporation's lead drug, Yutrepia, for pulmonary hypertension, is seeing early commercial traction and milestone progress due to its delivery and tolerability advantages. This has shifted Liquidia's investment narrative, with key catalysts including continued prescription uptake and reaching a US$100 million net sales milestone. However, investors must consider high valuation multiples, ongoing losses, and execution risks.
Liquidia (NASDAQ:LQDA) Rating Lowered to Hold at Wall Street Zen
Wall Street Zen downgraded Liquidia (NASDAQ:LQDA) from a "buy" to a "hold" rating, despite other analysts maintaining "buy" or "strong-buy" ratings with higher price targets. The company recently reported better-than-expected quarterly earnings and revenue. However, a significant amount of insider selling has occurred, which could raise investor concerns.
Campbell & CO Investment Adviser LLC Takes Position in Liquidia Corporation $LQDA
Campbell & CO Investment Adviser LLC has acquired a new position in Liquidia Corporation ($LQDA), purchasing 89,086 shares valued at approximately $2.03 million in the third quarter of 2025. This move brings institutional ownership of Liquidia to about 64.54%. Despite significant insider selling over the past 90 days, Liquidia has beaten revenue and EPS estimates and received multiple analyst upgrades, earning it a "Moderate Buy" consensus rating with an average target price of $39.67.
Liquidia (NASDAQ:LQDA) Reaches New 1-Year High - Here's What Happened
Liquidia (NASDAQ:LQDA) reached a new 52-week high of $41.57 on Friday, driven by strong earnings that beat analyst expectations with a 1106.7% year-over-year revenue increase. Analysts have responded by raising price targets, contributing to a "Moderate Buy" consensus rating and a $39.67 price target. Despite insider selling activity totaling over $11 million in the last quarter, institutional investors have increased their positions in the company, which specializes in pulmonary arterial hypertension treatments.
Liquidia’s YUTREPIA Launch Turned A Small Biotech Into A Sales Story
Liquidia Corporation saw its shares jump 185% over the past year following the FDA approval and commercial launch of its headline product, YUTREPIA. This success has fueled significant revenue growth and improved cash flow for the biotech company, which focuses on treatments for rare cardiopulmonary diseases. Despite strong growth prospects and a differentiated technology platform, Liquidia faces challenges including a lofty valuation, ongoing unprofitability, and intense competition in the market.
Liquidia (NASDAQ:LQDA) Upgraded by Zacks Research to Strong-Buy Rating
Zacks Research has upgraded Liquidia (NASDAQ:LQDA) from a "hold" to a "strong-buy" rating, with other firms also raising their price targets, leading to an average target of approximately $39.67. The company reported better-than-expected quarterly EPS and strong revenue growth but remains unprofitable. Insider sales totaling around $11.0 million have occurred in the last 90 days, while institutional investors hold a significant portion of the stock.
LQDA: Achieved rapid profitability and 25% market share in seven months, with major growth ahead
Liquidia Corporation (LQDA) achieved profitability in its first quarter of launch and rapidly gained a 25% market share. The company's growth is driven by Yutrepia and L606 through new indications and clinical studies, with future plans to double manufacturing capacity and expand globally. This information is based on Liquidia's 44th Annual J.P. Morgan Healthcare Conference Audio Transcript from January 15, 2026.
Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 66,610 Shares
Liquidia CEO Roger Jeffs sold 66,610 shares of Liquidia (NASDAQ:LQDA) stock for over $2.49 million, reducing his stake by about 6.03%. Several other executives also sold shares the same day. Despite these insider sales, Liquidia's stock traded up by approximately 4.1% to $38.09, following a significant quarterly earnings beat, while analysts generally maintain a bullish outlook with an average target price of $39.67.
Liquidia corp general counsel sells $1m in shares
Liquidia Corp's General Counsel, Russell Schundler, sold 27,289 shares of common stock for over $1 million. This sale, executed under a Rule 10b5-1 trading plan, occurred while the company's stock trades near its 52-week high after an impressive 235% return over the past year. Despite not being profitable in the last twelve months, Liquidia boasts strong gross profit margins and significant revenue growth from its product, Yutrepia, leading to raised price targets from analysts.
Liquidia corp general counsel sells $1m in shares By Investing.com
Liquidia Corp's General Counsel, Russell Schundler, sold 27,289 shares totaling over $1 million on January 12, 2026, and also exercised options for 29,395 shares earlier in the month. This transaction happened as the stock trades near its 52-week high, having returned 235% over the past year. Analyst firms Jefferies and BTIG have maintained Buy ratings on Liquidia, with raised price targets, following strong preliminary Q4 results for their product Yutrepia.
Liquidia’s chief business officer Adair sells $507k in LQDA stock
Liquidia's Chief Business Officer, Jason Adair, sold 13,548 shares of LQDA common stock for $507,101 on January 12, 2026, under a pre-arranged trading plan. This follows his acquisition of 21,854 shares through the conversion of Performance Stock Units on January 9, 2026. Separately, Liquidia reported strong preliminary fourth-quarter 2025 revenue for its Yutrepia inhalation powder of $90.1 million, exceeding expectations and leading to raised price targets from analysts.
Liquidia corp general counsel sells $1m in shares
Liquidia Corp's General Counsel, Russell Schundler, sold 27,289 shares of common stock for over $1 million, executed under a Rule 10b5-1 trading plan. This transaction occurred as the company's stock trades near its 52-week high, having delivered a significant 235% return over the past year. Despite not being profitable in the last twelve months, Liquidia boasts impressive gross profit margins and has seen strong preliminary Q4 results, leading to raised price targets from analysts.
Liquidia (NASDAQ:LQDA) CFO Sells $1,382,364.76 in Stock
Liquidia (NASDAQ:LQDA) CFO Michael Kaseta sold 36,932 shares of the company's stock for $1,382,364.76 on January 12th, decreasing his holding by 9.52%. Several other insiders, including CEO Roger Jeffs, also sold significant stakes around the same time. Despite the insider selling, Liquidia reported strong revenue growth (up 1,106.7% YoY) and analysts maintain a "Moderate Buy" rating with an average target price of ~$39.67.
Liquidia (NASDAQ:LQDA) Insider Sells $492,765.95 in Stock
Liquidia insider Sarah Krepp sold 13,165 shares of the company's stock for $492,765.95 on January 12th, reducing her stake by 8.55%. Other executives, including the CEO, CFO, and General Counsel, also sold significant amounts of stock around the same time and price. Despite these insider sales and negative earnings, Liquidia holds a "Moderate Buy" consensus rating from analysts with an average target price near $39.67.
Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells 13,548 Shares of Stock
Liquidia insider Jason Adair sold 13,548 shares of the company's stock at an average price of $37.43, totaling over $507,000, reducing his stake by 6.85%. This sale is part of broader insider selling activity at Liquidia, with the CEO, CFO, and General Counsel also selling significant shares. Despite the insider selling, analysts hold a "Moderate Buy" consensus rating for LQDA with a mean price target around $39.67, following a quarter where the company surpassed revenue estimates.
Liquidia (LQDA): Buy the breakout or wait for pullback?
Liquidia Corporation (LQDA) is a biopharmaceutical company trading on Nasdaq, whose stock performance is analyzed using Elliott Wave theory. The analysis suggests LQDA is extending a rally in an impulse wave and is expected to reach the $38.16 – $40.90 area before a correction begins. The article advises buying on pullbacks in 3, 7, or 11 swings at extreme areas, or on a potential wave II correction.
Analyst Expectations For Liquidia's Future
Five analysts have recently provided ratings for Liquidia (NASDAQ: LQDA), with an average 12-month price target of $49.8, representing a 14.22% increase from the previous average. Several analysts from BTIG, HC Wainwright & Co., and Needham have maintained or raised their ratings to 'Buy' with adjusted price targets. The article also details Liquidia's financial performance, highlighting strong revenue growth of 1121.72% as of September 30, 2025, and an excellent net margin of -6.5%, though its ROE, ROA, and debt-to-equity ratio are below industry averages.
